STAT3 and neoplasm: On the other hand, ongoing suppression of JAK2/STAT3 activation with daily momelotinib administration in Phase 3 as a ‘maintenance therapy’ substantially reduced the tumor burden, and drastically improved the disease-free survival in 50% of the mice; while the other 50% mice demonstrated significantly less tumor burden compared to control and Group 2 mice tumors and had a significantly prolonged disease-free survival period.